Participants 56 128 4
metastatic and/or unresectable malignant gastrointestinal stromal tumors
Participants 351 454 4
patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)
Participants 606 656 3
patients with progressive disease on a lower dose.
Participants 793 917 5
European Organization for Research and Treatment of Cancer (n = 946) and the other by the Southwest Oncology Group (n = 746)
